Results 21 to 30 of about 3,675 (177)

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy [PDF]

Science Advances, 2023
Reactivation of the latent HIV-1 reservoir is a first step toward triggering reservoir decay. Here, we investigated the impact of the BAF complex inhibitor pyrimethamine on the reservoir of people living with HIV-1 (PLWH). Twenty-eight PLWH on suppressive antiretroviral therapy were randomized (1:1:1:1 ratio) to receive pyrimethamine, valproic acid ...
Prins, Henrieke A. B., Crespo, Raquel, Lungu, Cynthia, Rao, Shringar, Li, Letao, Overmars, Ronald J., Papageorgiou, Grigorius, Mueller, Yvonne M., Stoszko, Mateusz, Hossain, Tanvir, Kan, Tsung Wai, Rijnders, Bart J. A., Bax, Hannelore I., van Gorp, Eric C. M., Nouwen, Jan L., de Vries-Sluijs, Theodora E. M. S., Schurink, Carolina A. M., de Mendonça Melo, Mariana, van Nood, Els, Colbers, Angela, Burger, David, Palstra, Robert-Jan, van Kampen, Jeroen J. A., van de Vijver, David A. M. C., Mesplède, Thibault, Katsikis, Peter D., Gruters, Rob A., Koch, Birgit C. P., Verbon, Annelies, Mahmoudi, Tokameh, Rokx, Casper   +30 more
openaire   +6 more sources

A CRISPR Screen of HIV Dependency Factors Reveals That CCNT1 Is Non-Essential in T Cells but Required for HIV-1 Reactivation from Latency

Viruses, 2023
We sought to explore the hypothesis that host factors required for HIV-1 replication also play a role in latency reversal. Using a CRISPR gene library of putative HIV dependency factors, we performed a screen to identify genes required for latency ...
Terry L. Hafer, Abby Felton, Yennifer Delgado, Harini Srinivasan, Michael Emerman   +4 more
doaj   +1 more source

NSC95397 Is a Novel HIV-1 Latency-Reversing Agent

Viruses, 2023
The latent viral reservoir represents one of the major barriers to curing HIV-1. Focus on the “kick and kill” (also called “shock and kill”) approach, in which virus expression is reactivated, and then cells producing virus are selectively depleted, has led to the discovery of many latency-reversing agents (LRAs) that have furthered our understanding ...
Randilea Nichols Doyle, Vivian Yang, Yetunde I. Kayode, Robert Damoiseaux, Harry E. Taylor, Oliver I. Fregoso   +5 more
openaire   +6 more sources

Mechanism by Which PF-3758309, a Pan Isoform Inhibitor of p21-Activated Kinases, Blocks Reactivation of HIV-1 Latency

Biomolecules, 2023
The “block and lock” strategy is one approach that might elicit a sterilizing cure for HIV-1 infection. The “block” refers to a compound’s ability to inhibit latent HIV-1 proviral transcription, while the “lock” refers to its capacity to induce permanent
Benni Vargas, James Boslett, Nathan Yates, Nicolas Sluis-Cremer   +3 more
doaj   +1 more source

A Two-Color Haploid Genetic Screen Identifies Novel Host Factors Involved in HIV-1 Latency

mBio, 2021
To identify novel host factors as putative targets to reverse HIV-1 latency, we performed an insertional mutagenesis genetic screen in a latent HIV-1 infected pseudohaploid KBM7 cell line (Hap-Lat).
Michael Röling, Mahsa Mollapour Sisakht, Enrico Ne, Panagiotis Moulos, Raquel Crespo, Mateusz Stoszko, Elisa De Crignis, Helen Bodmer, Tsung Wai Kan, Maryam Akbarzadeh, Vaggelis Harokopos, Pantelis Hatzis, Robert-Jan Palstra, Tokameh Mahmoudi   +13 more
doaj   +1 more source

Latency reversal and viral clearance to cure HIV-1 [PDF]

Science, 2016
Next steps toward curing HIV-1 Since the discovery of HIV-1 more than 30 years ago, prevention and treatment strategies have dominated the research agenda. More recently, however, scientists are also focusing their efforts toward finding a cure. Margolis et al.
David M, Margolis, J Victor, Garcia, Daria J, Hazuda, Barton F, Haynes   +3 more
openaire   +2 more sources

Human Immunodeficiency Virus-1 Latency Reversal via the Induction of Early Growth Response Protein 1 to Bypass Protein Kinase C Agonist-Associated Immune Activation

Frontiers in Microbiology, 2022
Human Immunodeficiency Virus-1 (HIV) remains a global health challenge due to the latent HIV reservoirs in people living with HIV (PLWH). Dormant yet replication competent HIV harbored in the resting CD4+ T cells cannot be purged by antiretroviral ...
Lilly M. Wong, Dajiang Li, Yuyang Tang, Gema Méndez-Lagares, George R. Thompson, Dennis J. Hartigan-O’Connor, Satya Dandekar, Guochun Jiang, Guochun Jiang   +8 more
doaj   +1 more source

Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Signaling pathways play a key role in HIV-1 latency. In this study, we used the 24ST1NLESG cell line of HIV-1 latency to screen a library of structurally diverse, medicinally active, cell permeable kinase inhibitors, which target a wide range of signaling pathways, to identify inhibitors of HIV-1 latency reversal.
Benni, Vargas, Nicholas S, Giacobbi, Anwesha, Sanyal, Narasimhan J, Venkatachari, Feng, Han, Phalguni, Gupta, Nicolas, Sluis-Cremer   +6 more
openaire   +2 more sources

Inconsistent Reversal of HIV-1 Latency Ex Vivo by Antigens of HIV-1, CMV, and Other Infectious Agents [PDF]

Retrovirology, 2020
Abstract BackgroundA reservoir of replication-competent but latent virus is the main obstacle to a cure for HIV-infection. Much of this reservoir resides in memory CD4 T cells. We hypothesized that these cells can be reactivated with antigens from HIV and other common pathogens to reverse latency.
Thomas Vollbrecht, Aaron O. Angerstein, Bryson Menke, Nikesh M. Kumar, Michelli Faria de Oliveira, Douglas D. Richman, John C. Guatelli   +6 more
openaire   +8 more sources

Moving Toward a Functional Cure for HIV-1

Infectious Diseases & Immunity, 2021
. Despite the recent success of suppressing human immunodeficiency virus 1 (HIV-1) replication in the peripheral blood with antiretroviral therapy, elimination of the provirus from infected cells remains challenging because the virus can integrate into ...
Wen Kang, Yongtao Sun, Haijuan Wang
doaj   +1 more source